Cancer specific risk in multiple sclerosis patients
| Autor: | Kyritsis, A. P., Boussios, Stergios, Pavlidis, Nicholas |
|---|---|
| Přispěvatelé: | Pavlidis, Nicholas [0000-0002-2195-9961], Boussios, Stergios [0000-0002-2512-6131] |
| Rok vydání: | 2016 |
| Předmět: |
Risk
Oncology Immunomodulating agent medicine.medical_specialty Multiple Sclerosis Ovary cancer Population Review Multiple sclerosis Immunomodulation Cancer risk 03 medical and health sciences Prostate cancer Breast cancer 0302 clinical medicine Neoplasms Internal medicine medicine Humans Corticosteroid Skin cancer education Risk assessment education.field_of_study Digestive system cancer Bladder cancer Respiratory tract cancer business.industry Cancer Hematology medicine.disease Brain tumor Malignant neoplastic disease Immunosuppressive agent 030220 oncology & carcinogenesis Immunology business Complication 030217 neurology & neurosurgery Human |
| Zdroj: | Critical reviews in oncology/hematology |
| ISSN: | 1040-8428 |
| DOI: | 10.1016/j.critrevonc.2015.10.002 |
| Popis: | Multiple sclerosis (MS) is a chronic central nervous system (CNS) autoimmune disease. Studies of cancer risk in MS patients have shown inconsistent findings. A pubmed search of the literature on cancer risk in patients with MS was conducted and found published relative studies. The majority of these studies concluded that there was overall either reduced or no increased risk of developing malignancies between patients with MS compared to the general population. However, several studies suggested that patients with MS may have reduced risk in specific cancers such as of the digestive and respiratory organs, prostate, ovary, or increased risk in breast, brain and bladder tumors. At present it is uncertain if the immunologic profile of MS patients may be related to the increased or reduced frequency of some cancers and warrants further investigation. © 2015 Elsevier Ireland Ltd. 98 29 34 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect